The success of Sildenafil initially fueled a boom for major pharmaceutical companies, but recent changes present a complicated outlook for shareholders. Off-patent versions are eroding earnings, and persistent patent https://ronaldaome316377.blogzag.com/84553170/sildenafil-and-big-pharma-a-risky-bet